ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

This study is designed to compare the safety and efficacy of ASKC202 combined with Limertinib Versus platinum-based chemotherapy in locally advanced or metastatic NSCLC With MET Amplification/Overexpression after disease progression on EGFR tyrosine kinase inhibitor.

NCT Number	NCT07109531
Lead Sponsor	Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Conditions	Locally Advanced or Metastatic NSCLC
Enrollment	286 participants
Start Date	2025-08-31
Primary Completion	2027-10-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-08-07